TriangleHPV ctDNA Response based radiation (NCT07425054)
HPV ctDNA Response based radiation trial for Anal Cancer (NCT07425054). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with untreated, locally advanced squamous-cell cancer of the anus, without distant spread.
The idea: HPV DNA in blood after four weeks of chemoradiation guides radiation duration. Favorable, intermediate, and unfavorable groups receive 28, 30, or 34 fractions. Chemotherapy combines mitomycin with either capecitabine or fluorouracil. Only the unfavorable group adds retifanlimab after chemoradiation, every four weeks for up to a year. It blocks PD-1, aiming to restore T-cell responses against cancer.
This phase 2 study plans 33 patients. Jennifer Dorth leads; Cleveland has the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.